Keros Therapeutics, Inc.
KROS
$9.93
-$0.14-1.39%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 33.18M | 244.06M | 246.72M | 232.84M | 214.71M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 33.18M | 244.06M | 246.72M | 232.84M | 214.71M |
| Cost of Revenue | 96.93M | 129.54M | 157.36M | 187.07M | 184.08M |
| Gross Profit | -63.75M | 114.52M | 89.36M | 45.78M | 30.63M |
| SG&A Expenses | 46.50M | 46.85M | 45.77M | 45.46M | 40.94M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 143.43M | 176.39M | 203.13M | 232.53M | 225.02M |
| Operating Income | -110.25M | 67.67M | 43.59M | 312.00K | -10.31M |
| Income Before Tax | -90.31M | 91.90M | 71.15M | 26.89M | 14.56M |
| Income Tax Expenses | -5.16M | 4.88M | 6.70M | 8.12M | 10.34M |
| Earnings from Continuing Operations | -85.15 | 87.01 | 64.45 | 18.77 | 4.21 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -85.15M | 87.01M | 64.45M | 18.77M | 4.21M |
| EBIT | -110.25M | 67.67M | 43.59M | 312.00K | -10.31M |
| EBITDA | -108.68M | 69.18M | 45.03M | 1.67M | -9.01M |
| EPS Basic | -3.01 | 1.86 | 1.58 | 0.35 | -0.14 |
| Normalized Basic EPS | -1.97 | 1.23 | 1.09 | 0.35 | 0.07 |
| EPS Diluted | -3.01 | 1.82 | 1.54 | 0.31 | -0.18 |
| Normalized Diluted EPS | -1.97 | 1.20 | 1.07 | 0.32 | 0.04 |
| Average Basic Shares Outstanding | 128.06M | 148.99M | 162.13M | 159.10M | 154.59M |
| Average Diluted Shares Outstanding | 128.06M | 149.46M | 162.60M | 159.56M | 155.05M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |